Uses of BNIPXL-beta in premature canities
US8178293B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2009 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | Apr 28, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61Q5/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXLβ, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXLβ, said part comprising at least 18 nucleotides.The invention also concerns methods for screening molecules modulating the expression of a gene coding for BNIPXL-beta and molecules modulating the activity of the BNIPXL-beta polypeptide, in order to identify an agent for use for cosmetic or therapeutic purposes in the field of pigmentation. The invention also encompasses various uses of molecules which may be identified by these methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.